The association between non-ventilator associated hospital acquired pneumonia and patient outcomes among U.S. Veterans
•NV-HAP leads to longer length of stay and higher mortality and health care costs.•Data available at admission is insufficient for risk stratification.•Approximately 20% of all sepsis cases were associated with NV-HAP.•Evidence-based prevention efforts should target all hospitalized patients. Non-ve...
Saved in:
Published in | American journal of infection control Vol. 50; no. 12; pp. 1339 - 1345 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.12.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | •NV-HAP leads to longer length of stay and higher mortality and health care costs.•Data available at admission is insufficient for risk stratification.•Approximately 20% of all sepsis cases were associated with NV-HAP.•Evidence-based prevention efforts should target all hospitalized patients.
Non-ventilator associated hospital acquired pneumonia (NV-HAP) affects approximately 1 in 100 hospitalized patients yet risk-adjusted outcomes associated with developing NV-HAP are unknown.
Retrospective cohort study with propensity score matched populations (NV-HAP vs no NV-HAP), using ICD-10 codes for bacterial pneumonia not present on admission. Outcomes included the patient level probability of NV-HAP developing among acute care non-transfer admissions in 133 Veterans Affairs hospitals and subsequent mortality, length of stay, inpatient sepsis, and 12-month costs.
NV-HAP occurred in 0.6% of Veteran admissions. Among admissions that developed NV-HAP, the mean length of stay of 26.3 days (6.72 days among non-NV-HAP), 30-day mortality was 18.4% (4.5% among non-NV-HAP), 1-year mortality was 47.8% (21.4% among non-NV-HAP), and total median 12-month direct medical costs were $138,136.32 ($64,357.21 among non-NV-HAP). Inpatient sepsis occurred in approximately 20% of NV-HAP admissions (0.7% among non-NV-HAP). Data available at admission was insufficient to identify high and low risk patient groups.
NV-HAP is associated with severely worse patient outcomes and increased costs of care up to 12 months post-episode. Since population risk stratification is not feasible, prevention efforts should be directed at the full population of hospitalized Veterans. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 0196-6553 1527-3296 |
DOI: | 10.1016/j.ajic.2022.02.023 |